Trial · NCT06868511

Neuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage

NCT06868511, Phase 3, Recruiting, Beijing Tiantan Hospital

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Neuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage. Trials, record NCT06868511. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06868511

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Neuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage
NCT number: NCT06868511
Status: Recruiting
Phases: Phase 3
Enrollment: 732 participants, estimated
Lead sponsor: Beijing Tiantan Hospital
Conditions: Deep Intracerebral Hemorrhage (ICH)
Interventions: Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined with Tenecteplase, Standard medical treatment
First posted: 2025-03-11
Last updated: 2025-04-22

Source ClinicalTrials.gov

Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Modified Rankin Scale (mRS) score of 0-3 at 180 days.	180 ±14 days	The primary efficacy outcome is the proportion of patients achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-3 at 180 days.
Secondary	Dichotomized eGOS (extended Glasgow Outcome Scale) score at 180 days: 4-8 (good) vs. 1-3(poor)	180 ± 14 days	Dichotomized eGOS (extended Glasgow Outcome Scale) score at 180 days: 4-8 (good) vs. 1-3 (poor). The eGOS is scored as: 1=Death, 2=Vegetative state, 3=Lower severe disability, 4=Upper severe disability, 5=Lower moderate disability, 6=Upper moderate disability, 7=Lower good recovery, 8=Upper good recovery.
Secondary	All-cause death at 180 days	180 ± 14 days	All-cause death at 180 days
Secondary	Dichotomized, modified Rankin Scale (mRS) Score 0-3 vs. 4-6 at 90 days.	90 ± 7 days	Proportion of patients with mRS of 0-3 (good functional status) at 90 days. The mRS is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. Dichotomized scores are: 0-3=No symptoms to moderate disability requiring some assistance; 4-6=Moderately severe disability requiring complete assistance to death.
Secondary	Dichotomized graded modified Rankin Scale (mRS) score at 180 days : 0-2 vs. 3-6.	180 ± 14 days	Dichotomized graded modified Rankin Scale (mRS) score at 180 days post-hemorrhage: 0-2 vs. 3-6. The mRS is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. Dichotomized scores are: 0-2=No symptoms to slight disability; 3-6=Moderate disability requiring some assistance to death.
Secondary	Ordinal graded modified Rankin Scale (mRS) score (0-6) at 180 days.	180 ± 14 days	Ordinal graded modified Rankin Scale (mRS) score (0-6) at 180 days. The mRS is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.
Secondary	Barthel Index (BI) assessment at 180 days.	180 ±14 days.	Barthel Index assessment at 180 days. The Barthel Index (BI) assesses ten functional tasks of daily living, and each task provides a measure for level of independence. Scores range from 0 and 100, with a higher score indicating greater independence.
Secondary	Extended Glasgow Outcome (eGOS) assessment at 180 days.	180 ± 14 days	Extended Glasgow Outcome (eGOS) assessment at 180 days. The extended Glasgow Outcome Scale (eGOS) is a global scale for functional outcome with eight categories: 1 - Death, 2 - Vegetative State, 3 - Lower Severe Disability, 4 - Upper Severe Disability, 5 - Lower Moderate Disability, 6 - Upper Moderate Disability, 7 - Lower Good Recovery, 8 - Upper Good Recovery.
Secondary	The change of the National Institutes of Health Stroke Scale (NIHSS) at 5-7 days or discharge if earlier from baseline.	5-7 days	The change of the National Institutes of Health Stroke Scale (NIHSS) at 5-7 days or discharge if earlier from baseline. Patients with a NIHSS score of less than 6 are considered to have a good recovery. The NIHSS is a 11-item scale that assesses language, motor function, sensory loss, consciousness, visual fields, extraocular movements, coordination, neglect, and speech. It is scored from 0 (no stroke symptoms) to 42 (severe stroke).
Secondary	Safety/Mortality - All-cause death at 30 days	Within 30 days.	All-cause death at 30 days

1 to 10 of 15Source ClinicalTrials.gov

See all 15 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT06868511

GET https://conductscience.org/api/trials/v1/NCT06868511/registered

API reference For AI assistants